JLE

Innovations & Thérapeutiques en Oncologie

MENU

Habits and therapeutic perceptions around HR+/ HER2 metastatic breast cancer in France, based on results from a national survey Volume 7, issue 1, January-February 2021

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

Tables

Authors
1 Hôpital Lyon Sud
Institut de cancérologie des Hospices civils de Lyon (IC-HCL)
Service d’oncologie
et Université de Lyon
65, chemin du Grand Revoyet
69310 Pierre Bénite
France
2 Assistance publique-Hôpitaux de Paris
Hôpital universitaire Saint-Louis
Sénopole
1, avenue Claude Vellefaux
75010 Paris
France
3 Centre Antoine Lacassagne
Service de recherche clinique
33, avenue de Valombrose
06100 Nice
France
4 European oncology medical unit
Eisai EFS
5, place de l’Iris
92400 Courbevoie
France
5 CHR Metz-Thionville
Hôpital Mercy
Service d’oncologie médicale
1, allée du Château
57530 Ars-Laquenexy
France
6 Institut Curie
Département d’oncologie médicale
35, rue Dailly
92210 Saint-Cloud
France
* Tirés à part
* Ces auteurs ont coordonné l’étude.

International expert guidelines recommend endocrine treatment with a CDK4/6 inhibitor as first-line treatment for HR+/HER2 advanced breast cancer. However, the levels of evidence and grades of recommendation are weaker for subsequent lines due to the lack of clinical trials evaluating overall therapeutic strategies. Treatment decisions are therefore based on the clinical expertise of the oncologist, which forms a key part of the evidence-based medicine. This observational study aims to describe and measure individual beliefs and habits in the choice of therapeutic strategies.